Biocept Inc.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients … Read more
Biocept Inc. (BIOCQ) - Total Assets
Latest total assets as of June 2023: $22.10 Million USD
Based on the latest financial reports, Biocept Inc. (BIOCQ) holds total assets worth $22.10 Million USD as of June 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biocept Inc. - Total Assets Trend (2019–2022)
This chart illustrates how Biocept Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biocept Inc. - Asset Composition Analysis
Current Asset Composition (December 2022)
Biocept Inc.'s total assets of $22.10 Million consist of 52.9% current assets and 47.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 41.8% |
| Accounts Receivable | $2.15 Million | 7.0% |
| Inventory | $757.00K | 2.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2022)
This chart illustrates how Biocept Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biocept Inc.'s current assets represent 52.9% of total assets in 2022, a decrease from 78.3% in 2019.
- Cash Position: Cash and equivalents constituted 41.8% of total assets in 2022, down from 52.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 7.0% of total assets.
Biocept Inc. Competitors by Total Assets
Key competitors of Biocept Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Biocept Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Biocept Inc. generates 0.84x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Biocept Inc. is currently not profitable relative to its asset base.
Biocept Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.81 | 3.81 | 3.81 |
| Quick Ratio | 1.70 | 3.55 | 3.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.96 Million | $ 20.11 Million | $ 20.11 Million |
Biocept Inc. - Advanced Valuation Insights
This section examines the relationship between Biocept Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.29 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -48.9% |
| Total Assets | $30.87 Million |
| Market Capitalization | $249.07 USD |
Valuation Analysis
Below Book Valuation: The market values Biocept Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biocept Inc.'s assets decreased by 48.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biocept Inc. (2019–2022)
The table below shows the annual total assets of Biocept Inc. from 2019 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $30.87 Million | -48.90% |
| 2021-12-31 | $60.42 Million | +27.32% |
| 2020-12-31 | $47.45 Million | +167.59% |
| 2019-12-31 | $17.73 Million | -- |